CRYSVITA (burosumab-twza)
FIBROBLAST GROWTH FACTOR 23 (FGF23) INHIBITORS, MONOCLON AB · X-LINKED HYPOPHOSPHATEMIC OSTEOMALACIA ·+1
ULTRAGENYX/KYOW
Drug class
Fibroblast Growth Factor 23 (FGF23) Inhibitors, Monoclon Ab
Fibroblast Growth Factor 23 (FGF23) Inhibitors, Monoclonal Antibodies, is a specialized class of targeted biologic agents designed to neutralize the activity of FGF23, a bone-derived hormone that regulates systemic mineral homeostasis. Read more about Fibroblast Growth Factor 23 (FGF23) Inhibitors, Monoclon Ab
2 drugs in this class 2 manufacturers
Drugs in Fibroblast Growth Factor 23 (FGF23) Inhibitors, Monoclon Ab
CRYSVITA (burosumab-twza)
FIBROBLAST GROWTH FACTOR 23 (FGF23) INHIBITORS, MONOCLON AB · X-LINKED HYPOPHOSPHATEMIC OSTEOMALACIA ·+1
KYOWA KIRIN, IN
Filter & compare in the drug finder →
Opens the drug finder with Fibroblast Growth Factor 23 (FGF23) Inhibitors, Monoclon Ab preselected. Add indication or manufacturer filters there.
Fibroblast Growth Factor 23 (FGF23) Inhibitors, Monoclonal Antibodies, is a specialized class of targeted biologic agents designed to neutralize the activity of FGF23, a bone-derived hormone that regulates systemic mineral homeostasis.
By binding directly to excess circulating FGF23, these monoclonal antibodies inhibit its suppressive effects on renal phosphate reabsorption and vitamin D activation, thereby increasing serum phosphorus levels and promoting normal bone mineralization.
While the term reflects a specific compendial and clinical classification rather than a formal FDA Established Pharmacologic Class, it is represented therapeutically by agents such as burosumab.
This class is primarily indicated for rare phosphate-wasting disorders, most notably X-linked hypophosphatemia and tumor-induced osteomalacia.
-
connectrx.com
Fibroblast Growth Factor 23 (FGF23) Inhibitors, Monoclonal Antibodies, is a specialized class of targeted biologic agents designed to neutralize the activity of FGF23, a bone-derived hormone that regulates systemic mineral homeostasis While the term reflects a specific compendial and clinical classification rather than a formal FDA Established Pharmacologic Class, it is represented therapeutically by agents such as burosumab
-
fda.gov
Fibroblast Growth Factor 23 (FGF23) Inhibitors, Monoclonal Antibodies, is a specialized class of targeted biologic agents designed to neutralize the activity of FGF23, a bone-derived hormone that regulates systemic mineral homeostasis By binding directly to excess circulating FGF23, these monoclonal antibodies inhibit its suppressive effects on renal phosphate reabsorption and vitamin D activation, thereby increasing serum phosphorus levels and promoting normal bone mineralization While the term...
-
arkansasbluecross.com
This class is primarily indicated for rare phosphate-wasting disorders, most notably X-linked hypophosphatemia and tumor-induced osteomalacia
-
nih.gov
This class is primarily indicated for rare phosphate-wasting disorders, most notably X-linked hypophosphatemia and tumor-induced osteomalacia
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.